These studies have collectively shown that ESR1 mutations present rarely in primary treatment-naive ER+ breast cancer, whereas they are highly prevalent in metastatic tumors, suggesting that these mutations may potentially arise from rare clones of primary tumors through clonal selection against endocrine therapy (ET)10–13. This evidence concerns the gene ESR1 and breast cancer.